YOUR BUSINESS AUTHORITY

Springfield, MO

Log in Subscribe

Pfizer ends agreement with Sangamo

Posted online

Pfizer has terminated a co-development agreement with Sangamo Therapeutics, the latter company announced on Monday.

The companies had planned to co-develop a hemophilia A gene therapy.

Sangamo is exploring options for the therapy, including the addition of a new partner.

Read more from Reuters.

Comments

No comments on this story |
Please log in to add your comment
Editors' Pick
Transportation officials discuss $471M Forward 44 initiative

Project work in Springfield corridor will continue into 2031.

Most Read
Update cookies preferences